Might a little-known sub-species of proteasome keep tau from tangling? On May 29 in Nature Neuroscience, scientists led by Kapil Ramachandran at Columbia University, New York, report that blocking the ...
Early dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer's disease. 02 Jun 2026 ...
Professional Information Research FellowMonash University Brain Waste, Please Proceed to Your Nearest Exit 29 May 2026 ...
A blood test may be almost as good as a brain scan for determining where someone lies along the Alzheimer’s disease continuum. So conclude scientists led by Gemma Salvadó and Oskar Hansson at Lund ...
Department of Geriatric Medicine Karolinska University Hospital Huddinge 141 86Stockholm Sweden Visit Website Contact: Professor Agneta Nordberg, Professor Lars-Olof Wahlund, Caroline Graff, Professor ...
Contact Information Brian Spencer, Ph.D. San Diego, United States Professional Information Assistant ProfessorUniversity of Southern California ...
This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...
A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...
Time to rewrite the brain anatomy textbook? In addition to the outermost dura, middle arachnoid, and innermost pia membranes surrounding the brain, researchers led by Kjeld Møllgård, University of ...
See Q&A With Claude Wischik. 2 October 2012. Remember Rember®—the blue dye that made headlines in 2008 when Phase 2 clinical trial data suggested it slowed decline in people with Alzheimer’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results